Wyss Institute awarded DARPA contract to further advance sepsis therapeutic device

March 25, 2013, Harvard University
Harvard's Wyss Institute awarded DARPA contract to further advance sepsis therapeutic device
The microfluidic "Spleen-on-a-chip" developed at the Wyss Institute at Harvard University will be used to rapidly treat bloodstream infections. Credit: Wyss Institute, Harvard University

The Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that it was awarded a $9.25 million contract from the Defense Advanced Research Projects Agency (DARPA) to further advance a blood-cleansing technology developed at the Institute with prior DARPA support, and help accelerate its translation to humans as a new type of sepsis therapy.

The device will be used to treat that are the leading cause of death in critically ill patients and soldiers injured in combat.

Harvard's Wyss Institute awarded DARPA contract to further advance sepsis therapeutic device
This image shows the microfluidic "Spleen-on-a-chip" developed at the Wyss Institute at Harvard University. Credit: Wyss Institute, Harvard University

To rapidly cleanse the blood of pathogens, the patient's blood is mixed with magnetic nanobeads coated with a genetically engineered version of a human blood 'opsonin' protein that binds to a wide variety of bacteria, fungi, viruses, parasites, and toxins. It is then flowed through microchannels in the device where pull out the bead-bound pathogens without removing human blood cells, proteins, fluids, or electrolytes – much like a human spleen does. The cleansed blood then flows back to the patient.

"In just a few years we have been able to develop a suite of new technologies, and to integrate them to create a powerful new device that could potentially transform the way we treat sepsis," said Wyss founding director and project leader, Don Ingber, M.D., Ph.D. "The continued support from DARPA enables us to advance our device manufacturing capabilities and to obtain validation in large animal models, which is precisely what is required to enable this technology to be moved towards testing in humans."

The team will work to develop manufacturing and integration strategies for its core pathogen-binding opsonin and Spleen-on-a-Chip fluidic separation technologies, as well as a novel called "SLIPS," which is a super- inspired from the slippery surface of a that repels nearly any material it contacts. By coating the inner surface of the channels of the device with SLIPS, blood cleansing can be carried out without the need for anticoagulants to prevent blood clotting.

In addition to Ingber, the multidisciplinary team behind this effort includes Wyss core faculty and Harvard School of Engineering and Applied Science faculty member Joanna Aizenberg, Ph.D., who developed the SLIPS technology; Wyss senior staff member Michael Super, PhD., who engineered the human opsonin protein; and Mark Puder, M.D., Ph.D., Associate Professor of Pediatric Surgery at Boston Children's Hospital and Harvard Medical School who will be assisting with animal studies.

Explore further: Novel coating that repels just about anything receives R&D 100 Award

Related Stories

Novel coating that repels just about anything receives R&D 100 Award

June 21, 2012
A novel coating that repels almost every type of liquid and solid, from blood and crude oil to ice and bacteria, has received a 2012 R&D 100 Award from R&D Magazine.

New 'magnetic yeast' marks step toward harnessing Nature's magnetic capabilities

February 28, 2012
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School have developed a method for inducing magnetic sensitivity in an organism that is not naturally magnetic—yeast. ...

Recommended for you

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.